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Abstract 
 
MicroRNAs (miRNAs) have been shown to affect 
haematopoietic differentiation, acting  as important determinants of 
cellular fate specification. 
The aim of this work is to investigate the role of miRNAs in the 
activation of T lymphocytes. By microarray analysis, we observed 
differential expression of miRNAs in distinct subclasses of T 
lymphocytes: CD8
+ 
naïve, CD8
+
 memory effector, CD8
+
central 
memory; CD4
+ 
naïve, CD4
+
 memory effector and CD4
+
 central 
memory. We found that miR-146a is expressed in separated primary T 
cells, in both CD4
+
 and CD8
+
 cells, but not in naïve T cells.  
Furthermore, a significative up-regulation of miR-146a expression 
levels was also obtained in the Jurkat T cell line, stimulated with 
αCD3-αCD28 antibodies, or with PMA and ionomycin, which are 
stimuli that mimic antigen recognition by TCR. 
Therefore, we attempted to discover the mechanisms of  miR-146a 
transcriptional regulation. Some indications about the pathways 
possibly involved were obtained by treatment of induced Jurkat cells 
with specific pharmacological inhibitors  of  pathways triggered by 
TCR signalling.. We found that Cyclosporine (CsA), a Calcineurin 
inhibitor, significantly impaired miR-146a up-regulation, thus 
suggesting that the pathways affected by CsA play a key role in the 
induction of miR-146a upon TCR engagement. This observation 
prompted us to further investigate with molecular tools the transcription 
factors which are responsible for miR-146a expression in T 
lymphocytes. A deeper investigation to carefully characterize the cis 
regulatory elements involved in miR-146a regulation was performed   
through a bioinformatic analysis of miR-146a promoter and a luciferase 
assay. These approaches allowed us to identify conserved consensus 
sites for T lymphocytes-specific transcription factors, which are 
involved in pathways triggered by TCR signalling and are required for 
miR-146a induction. The results obtained indicate that NF-κB  and c-
ETS are involved in miR-146a induction in T cell activation pathway. 
Moreover, we also demonstrated that miR-146a is also induced in 
Jurkat cells by an inflammatory stimulus, TNF-α treatment, and NF-κB 
is the main transcription factor responsible of miR-146a induction.  
Another intriguing aspect of miRNAs study is the identification of  
miRNAs biological role in a cell. We identified miR-146a targets 
 5 
taking advantage of a 3’-untranslated region (UTR) luciferase reporter 
assay. We tested a number of predicted miR-146a targets, relevant for T 
cell physiology. In particular, we report here that miR-146a down-
modulates the apoptosis process via translational inhibition of FADD 
and it reduces AP-1 transcriptional activity, through the down-
regulation of c-FOS  
Altogether, our findings reveal miR-146a involvement in T cell 
activation process, significantly affecting key properties of 
lymphocytes.  
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INTRODUCTION 
 
MICRORNAs: NEW KEY MODULATORS OF 
CELLULAR PROCESSES 
 
Gene regulation mediated by the action of small RNAs is a 
widely spread mechanism, evolutionarily conserved across diverse 
phyla, from prokaryotes to the more complex eukaryotes.This kind of 
regulation is present at many levels; several classes of small silencing 
RNAs have been identified thus far including small interfering RNAs 
(siRNAs), Piwi-interacting RNAs (piRNas) and microRNAs 
(miRNAs). 
MiRNAs are an abundant class of small silencing RNAs, whose 
functional role in many biological processes have been emerged in the 
last decade. It was long known in the Caenorhabditis elegans 
community that a decrease in the expression of the heterochronic gene 
lin-14, regulating developmental timing, was critical for early larval 
stage transition and that the lin-4 gene was required to reduced lin-14 
levels and allow the larval transition to occur
1
. In 1993 a 
groundbreaking work by two groups showed that repression occurred 
through complementary binding of small RNA lin-4 to the 3’-UTR 
(untranslated region) of the lin-14 mRNA 
2,3
. In working to clone the 
line-4 gene, Lee, Feinbaum, Ambros rigorously narrowed down the 
genomic interval of interest and systematically mutated all ORFs there 
to demonstrate that the line-4 gene product is not a protein.  Instead, 
they found the line-4 gene product is a small ncRNA that shows 
antisense complementarily of the line-14 3’-UTR 
1
.  A later study found 
and cloned a gene, let-7, that encodes a similar small ncRNA which 
acts in a similar manner 
4
. Numerous miRNAs have been cloned in the 
following years  and  they have shown to negatively regulate protein 
translation. 
MiRNAs are small endogenous non coding RNAs of about 22 
nucleotides in length involved in the post-transcriptional regulation. 
They derive from long primary transcripts (pri-miRNA), which can
 
exceed 1 kb and typically are transcribed by polymerase II 
5
. These pri-
miRNA are processed into hairpins of 60-70 nucleotides in length, 
called pre-miRNA by a complex containing the nuclear RNAse III 
 7 
enzyme Drosha and DGCR (Di Gorge Sindrome Critical Region 8 
homologue); they are then exported to the cytoplasm and further 
processed by an enzymatic complex containing the RNAse III enzyme 
Dicer and TRBP (human immunodeficiency virus 1-transactivating 
response RNA-binding protein)
 
yielding  the mature, double stranded, 
22 nucleotides long miRNAs 
6,7 
(Fig.A). 
Using one strand of the miRNA, called the guide strand, the miRISC is 
believed to either block mRNA translation, reduce mRNA stability or 
induce mRNA cleavage, after imperfect binding between the 5’-end of 
the miRNA and complementary sequence, in the 3’-UTR of the target 
mRNA,
 
(Fig.A) 
8,9
. Interaction specificity relies on the nucleotides 
occupying positions 2 to 7 or 2 to 8 within the miRNA. This region is 
called “seed” 
8,9
. Significantly, this redundancy within the 
miRNA:mRNA binding region means that individual miRNAs are able 
to target multiple mRNA and has led to the speculation the miRNAs 
might have a similar role to transcription factors 
10,11
. 
It is generally assumed that members of the same family of miRNA 
(i.e. sharing the same seed sequence) will affect the same targets. 
In the last few years 678 mature human miRNA sequences have been 
listed in the miRNA registry (http://www.microrna.sanger.ca.uk 
/sequences) with approximately 1000 predicted miRNAs, each 
potentially targeting about 200 genes 
12
. Therefore, it is estimated that  
the expression of >30% of the human genome may be regulated by 
miRNAs. 
 8 
 
 
Fig. A: Biogenesis of MiRNAs                                 Nat. Rev. Genet., 5, 522-531 
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MicroRNAs in haematopoiesis and in the immune response 
 
Study of miRNAs flourished during the last decade and it is now 
apparent that they can potentially modulate every aspect of cellular 
activity, targeting genes involved in a wide range of physiological 
processes, from apoptosis 
13
 to proliferation
14
 and differentiation 
15
. 
Many vertebrates miRNAs are expressed in a tissue- or cell type-
specific manner 
7
; for example miR-142 is primarily expressed in 
lymphoid cells 
16
, miR-223 is preferentially expressed in myeloid 
cells
17
 and miR-1 is expressed in the muscle 
15
. These findings are 
consistent with a role of microRNAs as tissue identity specificators.  
MiRNAs also participate to the regulation of haematopoietic 
differentiation, acting  in a lineage and developmental stage-specific 
manner
18,19
. This has emerged from studies that revealed selective 
expression of miR-181 in the thymus and miR-223 in the bone marrow 
and indicated their involvement in the differentiation of pluripotent 
hematopoietic stem cells (HSCs) into the various blood cells lineages, 
including B and T cells 
19,21
 (Fig. B). 
Some microRNAs are important to fine tune lymphoid-specific 
pathways; for example it has been shown that the over-expression of
 
miR-181 in haematopoietic precursor cells can bias
 
lymphoid 
differentiation toward the B cell lineage at the expense
 
of T cells 
19,22
.A 
significant role of microRNAs in the immune response has also been 
shown for miR-146a and miR-155; both of them are involved in the 
control of innate immunity, in response to pro-inflammatory 
stimuli
23,24
(Fig. B). 
Regulatory T (Treg) cells were also shown to express a distinct miRNA 
subset, which resembles a profile of miRNAs expressed in activated but 
not naive T cells 
19,20 
. 
The examples mentioned above suggest that, in addition to the effects 
of lineage specific transcription factors and cytokines, microRNAs 
affect  lymphoid differentiation, acting as important determinants of 
cellular fate specification 
19,21
. 
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Fig. B: Overview of the involvement of miRNAs in hematopoiesis and  immune 
system function 
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T LYMPHOCYTE ACTIVATION 
 
T lymphocyte activation is induced via the interaction of 
antigenic peptides, associated with major histocompatibility complex 
molecules (MHC) on the surface of antigen-presenting cells (APC), 
with the T cell receptor (TCR)/CD3 complex on T cells 
25
. A co-
stimulatory signal, mediated by the interaction of the auxiliary receptor 
expressed on T lymphocyte (CD28) with co-stimulatory molecules 
expressed by APC cells (B7.1 and B7.2), is also needed to achieve 
proper activation 
26
. 
TCR engagement by the antigen triggers a signal cascade which 
ultimately leads to the activation of transcription of several genes and 
induces the T lymphocytes to entry the cell cycle. 
TCR elicits its function through the regulation of phospholipase Cγ 
(PLCγ) an enzyme involved in the metabolism of inositol 
phospholipids
27
. The phosphorylation and following activation of this 
enzyme, occurring within minutes after antigen recognition, 
simultaneously induces the phosphatidyl-inositol and the DAG 
(diacylglycerol) signal transduction pathways. 
The first pathway triggers the activation of protein kinase Cθ which, in 
turn, leads the phosphorylation of several cytoplasmic proteins and 
induces the transcription of downstream genes, through the activation 
of two main transcription factors: AP-1 ( an heterodimeric 
transcriptional activator, composed of members of the Jun and Fos 
families) and NF-κB 
27,28 
(Fig. C).  
The DAG signal, generated from membrane phospholipids, elicits a 
sustained entry
 
of Ca
2+
 from the external milieu. The increase of the 
cytoplasmic Ca
2+
 concentration leads to gene transcription mediated by 
the
 
nuclear factor of activated T cells (NFAT)
29
.  
Finally, the synergic effects of these two signal transduction pathways 
induce transcription of interleukins, in particular IL-2, which is an 
important growth factor, fundamental to induce proliferation of 
activated T lymphocytes 
30
. 
Following activation by antigen presentation, T cells go through several 
phases:  
1) an interleukin-2 (IL2)- dependent proliferation of the cells (“clonal 
expansion”) and differentiation of the progeny in effector cells,  
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                                                           Adapted from Nature Reviews Immunology 3, 939-951 (2003) 
 
Fig. C: TCR signalling pathway   
 
 
2) an “effector phase”, in which T lymphocytes either provide help or 
kill infected target cells; 
3) a final “deletion phase”, in which most of the T cell clone 
eventually undergoes apoptosis, while few T cells survive and enter the 
memory T-cell pool. 
The proliferation of T lymphocytes in response to the antigenic 
stimulus is mediated by an autocrine loop: activated T cells produce 
cytokines (e.g. IL-2) and at the same time they express on their 
membrane the receptors for those cytokines 
30
. 
During the first phase T cells are resistant to apoptosis; entering the 
effector phase, T cells become progressively more sensitive to cell 
death in the presence of IL-2 and are finally deleted in the deletion 
phase. Therefore, IL-2 plays a dual role: it is firstly mandatory for 
clonal expansion and later for sensitizing T cells towards apoptosis 
31
. 
The isolation of cell lines suitable for the study of T-cell activation and 
maturation, together with the development of protocols for the 
PMA 
IONOMYCIN 
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activation of T-lymphocytes ex vivo, has allowed molecular 
characterization of the pathways involved 
32
.  
The leukemic Jurkat T-cell line has been central to most of the 
important discoveries in T-cell biology. Jurkat cells have been 
demonstrated to be very useful for the biochemical characterization of 
Antigen-TCR interaction and to investigate the related signal 
transduction pathways 
32
. Moreover, genetic studies in mice and the 
characterization of human immunodeficiencies reveal that the core 
aspects of TCR signalling which have been defined in Jurkat cell line 
are also relevant in a physiological setting 
2
 
In vitro study of T lymphocyte activation makes use of polyclonal 
activators (Fig. C), which bind to several TCR complexes, not 
depending on their specificity, mimicking the effect of the interaction 
with the complex MHC-peptide. For example, activation of T cells can 
be induced by signals generated by phorbol esters, such as PMA 
(activation of PKC) and ionomycin (induction of Ca
2+
 influx). The 
synergistic effect of these two signals leads to the activation of distinct 
signalling pathways which ultimately converge to induce IL-2 
transcription within 2-5 h from the beginning of the stimulation
33
. 
Therefore, these molecules bypass the interaction between antigen and 
lymphocyte, inducing the activation of signalling down-stream of both 
TCR and co-stimulatory pathway; for this reason they are widely used 
for in vitro studies. 
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REGULATION OF CYTOKINES SIGNALING 
AND INFLAMMATION 
 
In response to cell injury elicited by trauma or infection the 
inflammatory response sets in, constituting a complex network of 
molecular and cellular interactions detected to facilitate a return to 
physiological homeostasis and tissue repair. The response is composed 
of both local events and a systematic activation mediated by cytokines. 
If tissue health is not restored or in response to a stable low grad 
irritation, inflammation becomes a chronic condition, that continuously 
damages the surrounding tissues 
34
. 
The inflammatory response involves the sequential release of mediators 
and the recruitment of circulating leukocytes, which become activated 
at the inflammatory site and thus release further mediators. This 
response is self-limiting and in most cases it is resolved through the 
release of endogenous anti-inflammatory mediators and the clearance 
of inflammatory cells 
35
. The persistent accumulation and activation of 
leukocytes is a hallmark of chronic inflammation 
34, 36
. 
The cellular components of the inflammatory response include 
leukocytes (innate immune system) as well as lymphocytes T, B, NK 
(adaptive immune system). The first step in the initiation of the 
inflammatory response is the activation of the innate immune system. 
This non specific response serves to locate the injurious agent, restrict 
the tissue damage and eliminate the harmful agent, initiate the adaptive 
immune system and determine the path that will be followed (cellular / 
humoral response). As lymphocytes arrive to the inflammatory area, 
antigen-presenting cells (APCs) present infectious agent antigens of 
macrophages to T cells. This is the ignition signal for the activation of 
the adaptive immunity, consisting of cellular and humoral immunity. 
These cells co-operate using molecular signals, including cytokines, 
chemokines, vasoactive amines (histamine, serotonine), plasma 
proteases (kinine system, complement system), arachidonic acid 
metabolites (prostaglandins, leukotrienes, lipoxins), platelet-activating 
factor (PAF), nitric oxide (NO).  
Cytokines play important roles in the different phases of the immune 
response. In fact, they are responsible for the  induction and outcome of 
the inflammatory process, regulation of the acute phase response, 
initiation of lymphocyte activation, control of antibody production 
and/or generation of cytotoxic lymphocytes. 
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Cytokines are soluble factors which act as intercellular messenger 
between cells of the immune system by binding to specific receptors 
which are poorly expressed on resting cells and are up-regulated 
following cell activation. 
Each cell types is able to produce a specific set of cytokines and 
receptors in response to different stimuli; several receptors and 
cytokines can be expressed by different cell types, thus creating a 
network in which each cell produces, for a short period of time, a large 
variety of cytokines able to bind and stimulate different cells
 35
 
Cytokine receptors, consisting of two or more membrane protein 
subunits, can be separated in different classes including the 
hematopoietin receptor superfamily (e.g. receptor for IL-2, -4, -10), the 
Tumor-Necrosis-Factor receptor (TNF-R) superfamily, the Interferon- 
receptor (IFN-R) superfamily 
37
. Dimerization receptor subunits upon 
binding of the proper cytokine leads to the activation of the receptor 
associated cytoplasmic protein tyrosine kinases (JAKs) which either 
recruit members of the STAT family or activate the Ras-mitogen 
pathway 
37
. 
Tumor-Necrosis-Factor-a (TNF-α), interleukin-1b (IL-1b) and IL-6 are 
the classical pro-inflammatory cytokines. Their ability to activate both 
local and systemic effects is well established 
37
. Locally, they contribute 
to the activation of the inflammatory cells and together with 
chemokines, which induce the expression of adhesion molecules, cause 
their local recruitment. When the causes of the inflammatory reaction 
are of a high intensity, the production of cytokines is increased and they 
are released in the circulation provoking the “acute phase response”. On 
the other hand, “inhibitory” cytokines such as IL-10 damp down the 
activation of some effector functions of T lymphocytes and 
mononuclear phagocytes, by inhibiting the release of pro-inflammatory 
cytokines and therefore turning off the inflammatory process 
35
 . 
In fact, it was recently shown that IL-10, produced by T lymphocytes 
and macrophages can inhibit cytokine production in monocytes by 
blocking endotoxin-induced NF-κB activation, although the mechanism 
for this effect is unknown 
38
.  
NF-κB is thought to play a pivotal role in immune and inflammatory 
responses through the regulation of genes encoding pro-inflammatory 
cytokines, adhesion molecules, chemokines and growth factors 
39
. NF-
κB is usually kept inactive in the cytoplasm through association with 
endogenous inhibitor proteins of the I B (inhibitor of NF- B) family. In 
 16 
response to pro-inflammatory stimuli, such as TNF- , the signalling 
pathway converges on the activation of NF-κB 
40,41
. The NF-κB 
induction regulates both pro- and anti-apoptotic pathways. 
It was shown that NF-κB not only plays an essential role in the 
initiation of inflammation, allowing the production of inflammatory 
cytokines 
37
, but it is also involved in the resolution of inflammation, 
during which it induces the expression of anti-inflammatory genes and 
also induces apoptosis, thus turning off the inflammatory response 
42
. 
 
 
 
MiR-146a AND INFLAMMATION 
 
MiR-146 was first identified as an immune system modulator in a 
systematic effort to find miRNAs which influence the mammalian 
response to microbial infection 
23
. Exposure of human monocytic THP-
1 cells to various bacterial components, such as lipopolysaccharide 
(LPS) and peptidoglycan,  or to pro-inflammatory cytokines results in 
rapid induction of the expression of mature miR-146 
23
.  
Moreover, in B cells with latent infection with Epstein-Barr virus, miR-
146a expression increases as a result of signalling of the virus-encoded 
latent membrane protein 1 (LMP-1), which acts as a constitutively 
active homolog of the TNF-receptor 
43
. 
MiR-146 family is composed by two members: miR-146a and miR-
146b, located on separate chromosomes in the context of unrelated 
genes. These miRNAs differ in their mature sequence by just two 
nucleotides at the 3' end, suggesting that they could probably regulate 
the same target mRNAs. Transcription of both pri-miR-146a and pri-
miR-146b is up-regulated upon LPS stimulation 
23
, but only mature 
miR-146a is detected, suggesting that this miRNA family has a rather 
sophisticated mode of regulation of expression, involving more than 
one point of control. Promoter analyses have shown that transcriptional 
up-regulation of miR-146a, induced by Toll-like receptor-4 (TLR-4) 
and LMP-1, is NF- B dependent 
23,43
. Although the physiological 
functions of the miR-146 family are not yet fully defined, some 
interesting targets have been validated and support  a role for miR-146a 
in inflammation. In particular it was demonstrated that miR-146a is 
able to down-regulate the expression of IRAK1 and TRAF6 adaptor 
 17 
molecules, whose involvement in TLR signalling in monocytes is well 
established 
23
. 
Since both miR-146 targets (IRAK1 and TRAF6) act in the same linear 
signalling cascade, the cumulative effect of a drop in their protein 
abundance would probably have a considerable effect on TLR 
signalling and might be involved in regulation of the innate immune 
response. In addition, a microarray survey of miR-146a targets after its 
enforced over-expression in Akata B cell line has demonstrated miR-
146a-mediated inhibition of a group of interferon - responsive genes 
43
. 
Whether their regulation by miR-146a is direct or indirect remains to be 
determined. 
 
 
 
Activation-Induced Cell Death (AICD) in T cells 
 
T cell receptor is able to deliver multiple signals which lead to 
the induction of selective T cell functions by activating specific 
intracellular signaling pathways. In particular, TCR engagement in 
mature T lymphocytes triggers both proliferation and cell death. These 
two opposite outcomes are differentially regulated and both of them are 
fundamental for the maintenance of the homeostasis of the immune 
system.  
Thymocytes which fail to rearrange their TCR gene die by neglect 
43 
while those that recognize self-antigens are eliminated by apoptosis in a 
process called “negative selection” 
44
. 
In peripheral T cells, instead, the deletion of autoreactive T 
lymphocytes occurs by a form of apoptosis induced by repeated TCR 
stimulation 
45
. Furthermore, during an immune response, the majority 
of T lymphocytes, which undergo clonal expansion and proliferation in 
response to antigens in vivo, subsequently die by apoptosis, in order to 
maintain T cell homeostasis and self-tolerance 
45.
. 
The physiological process of efficient removal of these activated 
lymphocytes is known as Activation-Induced Cell Death (AICD) 
46
. It 
is now well established that AICD predominantly occurs by apoptosis, 
induced by repeated TCR stimulation
45,46
. 
Unless survival signals are received, AICD may be a default pathway in 
all activated T cells 
45,47
. Indeed, T cell activation leads to the increased 
expression of Fas antigen (CD95) and Fas ligand (FasL)
48
. 
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The Fas antigen is a death receptor and it belongs to the family of  
Tumor Necrosis Factor (TNF) receptor 
49
. Activated T cells expressing 
both Fas and FasL are killed either by themselves (“suicide”) or by 
interacting with each other (“fratricide”) 
50
. Although the Fas/FasL 
system is primarly used for AICD of CD4
+ 
cells, the TNF/TNF-R2 
system seems to substantially contribute to the elimination of CD8
+
 
cells 
51
. Moreover, AICD also involves perforin/granzyme B and it can 
occur in a caspase-independent manner 
52
. 
The functional relevance of Fas and FasL factors in AICD is underlined 
by the evidence that mice having mutations in either Fas or FasL show 
an abnormal accumulation of T cells in the periphery at about 8 weeks 
of age 
51
. Moreover, autoimmune diseases develop in mice and humans 
with inherited defects in Fas or FasL 
49,53
. 
Engagement of Fas by FasL results in aggregation of the receptor and 
recruitment of the cytoplasmic adaptor protein FADD (Fas- associated 
death domain) 
54
. 
The amino-terminal death effector domain (DED) of FADD interacts 
with  homologous DED within the prodomain of the initiator caspase 8, 
acting as a platform for its recruitment 
55
. 
Upon activation of the Fas receptor by FasL, FADD also recruits the 
initiator caspase-8 (also called FADD-like IL-1β- converting enzyme, 
FLICE)
55,56
. The Fas receptor, FADD and pro-caspase 8 form a 
functional Death-Inducing Signaling Complex (DISC). 
The activated caspase 8 is then released into the cytosol where it 
triggers the activation of a caspase cascade which initiates apoptosis 
55 
(Fig. D). 
In addition to TCR ligation, pharmacological drugs, such as phorbol 
esters (PMA) and Ca
2+
 ionophores (ionomycin), which mimic the two 
physiological signals (inositol 1,4,5-triphosphate and DAG, 
respectively) required for T cell activation, can also induce FasL 
expression and then AICD. For these reasons the use of these drugs 
represents a useful experimental approach to study the apoptotic 
process 
57
.  
.  
 19 
 
 
                                                                                                 Nature 1:50-58 (2001)       
Fig.D: Apoptosis cascade                     
 
                                                                   
                                                                     
                                                              
FADD adaptor protein in Apoptosis and beyond 
 
 
FADD (Fas Associated Death protein with Death Domain) is a 
key protein adaptor, transmitting the death signal mediated by death 
receptors. All the main death receptors, like TNF-R, Fas, TRAIL, 
require FADD adaptor for transmitting their apoptotic signal 
57
. 
Consequently, FADD is a crucial protein which controls multiple 
essential processes, including cellular homeostasis and elimination of 
 20 
pathological cells, particularly during the course of an immune 
response, both in mice and humans 
57
. 
Human and mouse FADD proteins are very similar; they consist of 208 
and 205 amino acids respectively and share 80% similarity and 68% 
identity 
58
. 
The pivotal role, that FADD plays in the apoptotic signalling of death 
receptor, was highlighted by generating mice with T cells that have 
germ line deficiency in FADD or those carrying a dominant negative 
form of FADD (FADDdd): they  are resistant to apoptosis
 58
. 
Biological functions of FADD are regulated via cellular sub-
localization, protein phosphorylation 
59,60
 and inhibitory molecules 
56
. 
Control of FADD recruitment to the DISC can occur following several 
mechanisms, depending on the cell type and the death receptor
 56
. The 
best characterized death receptor signaling inhibitor affecting FADD 
functions is the FLICE-inhibitory protein (c-FLIP) 
56
. 
Inhibition of death receptors- induced apoptosis by endogenous c-FLIP 
results from binding of c-FLIP to the death-effector-domain (DED) of 
FADD, thus hindering pro-caspase 8 activation.  
Therefore, the equilibrium between FADD and the expression of its 
inhibitors determines the outcome of the death receptor-stimulated 
cells: apoptosis or survival
 61
 (Fig.D). 
Besides its role in transmitting the apoptotic signal into the cell, FADD 
have been shown to be a multifunctional protein, implicated in survival/ 
proliferation and cell cycle progression 
62 
FADD-deficient mice are embryonic lethal with heart developmental 
problem and die around day 10 of gestation. Chimeric mice generated 
by injecting FADD-/- embryonic stem cells into the RAG-1-/- 
blastocysts do not develop any lymphoproliferative diseases. Analysis 
of these mice showed T cell development abnormalities and mature T 
lymphocytes lack the full potential to proliferate in response to TCR 
signals
 63
 . More recently, analysis of T-cell specific FADD deficient 
mice showed an inhibition of T cell development at the proliferative 
step between DN and DP transition 
64
. These observations suggest that 
FADD protein plays a role in mediating not only cell death signalling 
but T cell proliferation as well. 
It was demonstrated that FADD 
-/-
 peripheral T cells are cycling but are 
defective in their co-stimulatory response when stimulated. Analysis of 
several cell  cycle proteins showed normal down-regulation of p27 
inhibitor, but increased level of p21, decreased levels of cyclin D2 and 
 21 
constitutive activation of several cyclin-dependent kinases in activated 
T cells
 62
. However, further studies are necessary to elucidate the 
molecular mechanisms by which FADD targets the cell machinery  
It was supposed that the reduced proliferation resulted from the lack of 
IL-2 production or unresponsiveness to IL-2, but enzyme-linked 
immuno-absorbent assay (ELISA) did not show any alteration in IL-2 
levels
58
. Several characteristics of FADD-deficient chimeras are 
strikingly similar to those observed in IL-2Rβ-deficient mice, including 
the defect of T cell proliferation in response to IL-2, and a higher 
percentage of CD 69
+
 T cells 
58,62
. 
All these observations suggest a role for FADD in cytokine signaling 
and an unexpected link between cell proliferation and apoptosis. 
 
 
 
APOPTOSIS - REGULATING miRNAs: 
THE APOPTOMIRs 
 
 
Since the current knowledge on miRNAs world suggests that 
these small RNAs may modulate several biological processes, from 
differentiation to proliferation, it is not surprising that they also play an 
important role in regulating key steps of the apoptotic pathways by 
affecting the expression of  apoptosis-regulating genes. Thanks to the 
growing knowledge on this field, it is now quite clear that an increase 
number of miRNAs play a role in apoptosis. 
We refer to this class of Apoptosis-regulating miRNAs as 
“apoptomiRs”. 
The first miRNA described as an apoptotic regulator was the 
Drosophila gene bantam 
65
. It directly down-regulates the pro-apoptotic 
factor hid, suppressing the apoptotic activity. Furthermore, another 
miRNA, miR-14 was found to act as an anti-apoptotic factor by 
suppressing the death activator reaper during the eye formation
66
. 
Many efforts have been directed to identify miRNAs relevant for 
proliferation or cell death; for this purpose Cheng et al. individually 
knocked down 90 human miRs in HeLa and A459 cells 
67
. Among 
those miRNAs identified as regulators of apoptosis there was miR-21. 
This miRNA has been shown to down-regulate PTEN as well as 
PDCD4 and the pro-apoptotic tumor-suppressor p53 in cancer cells
68
. 
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In a groundbreaking work
 
it was shown an inverse correlation between 
miR-15a/miR16-1 expression and BCL-2 levels in CLL cells, providing 
the first evidence of direct miRNA modulation of apoptotic machinery 
in human tissue 
12
. Another microRNA which regulates BCL2 family 
members is miR-29a,b and c, which target MCL-1
69
. These few 
examples suggest that tight regulation of anti-apoptotic function 
through miRNA is critical in development and other cellular processes 
and the breaking of such equilibrium is a key event for the development 
of malignancies. 
Therefore, a single miRNA  is able to provide a significant survival 
advantage to cancer cells upon its deregulation, and this may be a 
fundamental mechanism, adopted by cancer cells to elude apoptotic cell 
death. On the other side, the alterations in the apoptotic pathways are 
detrimental also in non cancerous cells, because of the disrupted 
homeostasis inside a particular cellular compartment; for example in 
immune cells the altered equilibrium between life and death may lead 
to the development of autoimmune disorders.   
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MATERIALS AND METHODS 
 
 
Reagents. PD98059, SP600125 and Cyclosporine inhibitors were 
purchased from Sigma Aldrich. For  the isolation of CD4+ and CD8+ 
primary T lymphocytes: CD45RO, CD45RA or CD27 MicroBeads, and 
MACS
®
 Columns from Miltenyi Biotech (Bergisch Gladbach, 
Germany) Miltenyi MACS Purification kit was used. PE-
conjugated α-CD4, PE-cyanine (Cy) 7-conjugated anti-CCR7, FITC-
conjugated α-CD27, PE-conjugated α-CD127, allophycocyanin (APC)-
conjugated α-CD45RA, FITC-conjugated α-CD69, and control isotype-
matched antibodies were purchased from from BD Pharmigen (San 
Diego, CA). FITC-conjugated anti-CD45RO from Caltag Laboratories 
(Burlingame, CA). Dynabeads CD3/CD28 T Cell Expander 
(αCD3/CD28) from Dynal Biotech (ASA, Oslo, Norway). PMA and 
ionomycin from Sigma-Aldrich (Milan, Italy). TNF-α and IFN-α from 
Sigma-Aldrich (Milan, Italy). Recombinant IL-2 from Chiron 
(Amsterdam, Netherlands). MiR-146a over-expression was obtained by 
using Mimic-146a (Dharmacon) and Mimic scramble was used as 
control (Dharmacon). 
Ann-V was purchased from BD Biosciences and PI from Sigma 
Aldrich.  
 
Cell cultures.  The human leukemic T cell line, Jurkat (DSMZ) was 
used. Cells were grown in RPMI 1640 (Gibco) supplemented with 10% 
heat inactivated Foetal Bovine Serum (Sigma-Aldrich), Penicillin/ 
Streptomycin (Gibco) and L-glut (Gibco) at 37°C in 5% CO2.  
293T cells used for miR-146a targets identification were grown in D-
MEM (Gibco) supplemented with 10% Foetal Bovine Serum, Penicillin 
/ Streptomycin, and L-glut.  
 
 
Reverse transcription of mature miRNAs. qRT-PCR amplification of 
miRNAs was performed as described 
70 
with minor modifications: we 
used a different adapter sequence for each miRNA instead of the same 
sequence for all miRNAs. This modification allowed us to perform 
reverse transcription of all miRNAs in a given sample at the same time. 
Primers used are listed in Supplementary Table 1. 400ng of total RNA 
were denaturated for 3 minutes at 95º C and reverse transcribed with 
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the Superscript III RNAse H- Reverse Transcriptase (Invitrogen) for 30 
minutes at 50º C. 10µl reaction contained each RT primer at a final 
concentration of 0.1µM. Superscript enzyme was inactivated by 
incubation at 95º C for 5 minutes. Each reverse transcription primer 
consists of two different regions: the 3’region is 7 to 12nt long and is 
complementary to the 5’end of miRNA; the 5’region (herein referred to 
as adapter) is a 20 to 22nt sequence not represented in the mammalian 
genomes. 
 
qRT-PCR of mature miRNAs. RT reaction was brought to 800µl and 
10µl were used for each qPCR reaction. qPCR was performed with 
iCycler (BioRad) using iQ-SYBR-green supermix (BioRad) according 
to the manufacturers’ instructions. 
Forward primers for PCR amplification are 14 to 17nt long LNA 
modified DNA oligonucleotides 
70
. Three to five non consecutive 
nucleotides were LNA modified in the 5’end of each oligonucleotide. 
Melting temperature of LNA primers was checked at http://lna-
tm.com/. Reverse primers for PCR amplification are the reverse 
complementary sequence of adapters. PCR amplifications were 
performed in triplicates with a relative error of about 30%. 
Mature miRNAs were quantified with the standard curve method. 
Standard curves were obtained by qPCR amplification of serial 
dilutions of synthetic DNA templates. U6 small nuclear RNA was 
measured with the same method and used for normalization. Blank and 
RT minus controls were included. All oligonucleotides were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
 
Lentiviral transduction. Viral particles were obtained by co-
transfection of 293T cells with the pRRL-miR-146a construct (see 
DNA plasmid constructs) and the PLP-1, PLP-2 and PLP-VSVG 
plasmids. Medium was replaced 6 hrs after transfection, and viral 
particles were harvested 48 hrs after transfection. Jurkat cells were 
transduced overnight at a MOI of 15. Thereafter, cells were selected 
with 2µg /ml puromycin. 
 
RNA isolation. RNA used for mRNA and miRNA quantification 
analyses were obtained by a modified TRIzol method. Briefly, cell 
were suspended in TRIzol reagent (Invitrogen) and  processed 
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according to manufacturer’s protocol up through the addition of 
isopropanol. Samples were allowed to precipitate in isopropanol 
overnight at -20°C and then centrifuged at 12000x g for 15 min at 4°C. 
Isopropanol was decanted, samples were washed with ethanol 70% and 
then resuspended in nuclease- free water. 
 
Northern Blot. 30µg of total RNA were separated by electrophoresis in 
a 15% agarose gel and transferred to Gene Screen Plus nylon 
membrane, After 3 min of UV- cross linking, membranes were 
prehybridized for 2h at 50°C in the hybridization buffer (50% 
formamide, 6X SSC, 10X Denhart’s solution, 10mM EDTA, 0,1% SDS 
and 100 µg/ml single-stranded salmon sperm DNA). Hybridization was 
carried out overnight at 50°C with miR-146a probe (3x 10
6
 
cpm/ml).The probe was labeled with [γ-
32
P] deoxyoligonucleotide 
antisense to miR-146a, using T4 PNK system (NEB Biolabs). Then the 
membranes were washed 3 times with 2X SSC and 0,1X SDS for 20 
min and analyzed using IMAGEJ software for quantitative analyses and 
auto-radiographed on X-ray films (Kodak) using an intensifying screen 
at -80°C. After autoradiography the blot was reprobed with a probe for 
U6 as a loading control. 
 
Treatment with pharmacological inhibitors. Jurkat cells were pre-
incubated with CsA or PD98059 or SP600125 for 30 min before 
stimulation with αCD3-αCD28 antibodies. Various concentrations of 
inhibitors were used, as indicated in Fig.4a,b,c. Cells were harvested for 
RNA extraction 24h after stimulation.  
 
DNA plasmid constructs. miR-146a lentiviral construct was obtained 
as follows: a region of about 300 nt containing miR-146a was amplified 
from Jurkat cells genomic DNA and cloned into the BamHI Xho sites 
of a pcDNA 4 TO vector (Invitrogen). The MluI-XhoI fragment was 
PCR amplified and cloned into pSuperior-Puro (Oligoengine, Seattle) 
into the BstBI XhoI sites. The XmaI-XhoI fragment was finally cloned 
into the AgeI-XhoI sites in pRRLSIN.cPPT.PGK-GFP.WPRE 
(Addgene, plasmid #12252, Cambridge MA, USA) thus obtaining 
pRRLSIN.cPPT.PURO.CMV-TO-miR-146a.WPRE, herein referred to 
as pRRL-146a.  
 
 26 
Cloning of miR-146a promoter reporter constructs. The pmLuc-1 
AccepTor plasmid (Novagen) was used for generation of promoter 
reporter constructs. Briefly, the relevant regions were amplified by PCR 
from genomic DNA, using primers listed in supplementary table 1. 
PCR products were ligated into the pMLuc-1 AccepTor plasmid 
according to manufacturer instructions. Deletions were introduced 
using the site QuickChange II Site Directed Mutagenesis kit 
(Stratagene). Primers used for mutagenesis are listed in supplementary 
table1. The introduction of mutations was confirmed by DNA 
sequencing.  
 
Cloning of putative mir-146a targets UTR. A region encompassing 
about 300nt upstream and downstream of putative micro-RNA seed 
was amplified by PCR on genomic DNA with the following PCR 
protocol: 5x GoTaq Flexi buffer (Promega) 10µl MgCl (Promega) 3µl, 
10mM dNTPs (Promega) 1µl GoTaq (Promega) 0,25µl 10 µM Reverse 
and Forward oligos 1,25µl, genomic DNA 0,2µg and H2O to 50µl. The 
PCR program was as follows: 30 cycles (95°C for 30 sec, 58°C for 
45sec, 72°C for 60sec). PCR products were run on a 1% agarose gel to 
confirm amplified fragment size and then were purified on a 
Nucleospin column (Macheray-Nagel), digested with Xba I (New 
England Biolabs), purified on a G50 sephadex column (GE Healthcare, 
Amersham) and cloned into the Xba I site of pGL-3 plasmid 
(Promega). Positive clones were screened by PCR (10µl, same protocol 
as above) using the seqluc primer on the plasmid) and the UTR specific 
reverse primer. Positive clones were further confirmed by enzymatic 
digestion. Midi-preps of the plasmids were prepared with the Endofree 
Midi kit from Qiagen. 
 
Transient  transfection and Dual-luciferase reporter assay 
 
a) 146a promoter constructs. Lipid-mediated transfection was 
performed with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocols. Briefly,  Jurkat cells (5 x10
5
 cells/ ml) were 
plated in 6 well culture plates and transfected with 2µg pmLuc-1 
AccepTor plasmid (Novagen) containing the promoter fragment and 
2µg of pGL3TK  for normalization of transfection efficiency. After 24h   
recovery period, transfected cells were either left untreated or induced 
with TNF-α (40ng/ml; Roche Diagnostics) or αCD3 (5µg/ml; clone 
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OKT-3) and αCD28 (5µg/ml) or PMA (10ng/ml) and ionomycin 
(1µg/ml). The luciferase activity was assayed using a Dual-Luciferase 
Reporter Assay System (Promega) according to the manufacturer 
instructions. 
 
b) 3’UTR  of Target genes. 24 h before transfection 293T (1 x 10
5
 
cells/ 500µl) were plated in 24-well culture plates. The cells were then 
transfected with a pGL-3 vector containing the 3’ UTR of interest 
(0,26µg), a miR-146a mimic or a mimic scramble as a control and with 
a pRLTK vector (1,3ng) for normalization of transfection efficiency 
(Promega). The constructs were diluted in 50µl of OPTIMEM 
(Invitrogen) and added to 50µl of OPTI-MEM containing 2µl of 
Lipofectamine 2000 (Invitrogen) incubated 5 min at room temperature 
(RT). The mix was incubated at RT for 20 min and then added to the 
cells. Cells were collected and lysed with 100µl of Passive Lysis Buffer 
(Promega). The luciferase activity was assayed as described above 
 
 
 
Jurkat cells kinetics of Activation. 12 well-culture plate were coated 
over night at 4°C with a polyclonal rabbit anti-mouse immunoglobulins 
(Dako), 300µl in each well at the concentration of 10µg/ml. Wells were 
washed three times with cooled PBS and an equal concentration of 
αCD3 (5µg/ml) and αCD28 (5µg/ml) were added. The plates were 
incubated for 2-4h at 37°C or overnight at 4°C; afterward the wells 
were washed three times with the medium (RPMI1640, Gibco-
Invitrogen). Jurkats (5 x 10
5
  cells) were added to the wells and 
incubated for the indicated times.  
 
Bioinformatic analysis of  hsa pri-miRNA-146a promoter 
Bioinformatic analysis of the miR-146a 1100bp promoter region was 
performed using the MULAN software, available on line 
(www.mulan.dcode.org) 
 
CD69 staining. Jurkat and Jurkat pRRL-146a cells  (5x 10
5
 cells/ml) 
were washed in PBS, centrifuged at 1100 rpm for 10 min and 
resuspended in 50µl of PBS with 1µl of αCD69 FITC. The samples 
were incubated for 15 min at 4°C in the darkness and then were washed 
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twice with PBS. Cells were resuspended in 500µl of PBS and analyzed 
by FACS-Calibur (Becton Dickinson) 
 
T cell stimulation and cell death analysis. For the induction of AICD, 
Jurkat T cells (5x10
5 
cells/ml), transfected with mimic-146a or mimic 
scramble, were stimulated with PMA (100ng/ml) and ionomycin 
(1µg/ml) for 72h. Cells activation was measured by CD69 staining 4h 
after PMA and ionomycin induction. Apoptotic cell fractions were 
determined by annexin V-FITC and PI double staining according to the 
manufacturer’s instruction and analyzed with FACS-Calibur (Becton 
Dickinson). Unstained cells served as negative control. Data were 
analyzed using CellQuest software (Becton Dickinson) 
 
NF-κB reporter assay. Jurkat cells (4 x 10
5
 cells/ ml) were co-
transfected by Lipofectamine 2000 according to manufacturer’s 
protocol, with 3µg of NF-κB reporter construct (Promega) and with 3µg 
of the pGL3TK plasmid. 24h later cells were split in two wells of a 24- 
wells plate; one well was induced with αCD3-αCD28 antibodies. After 
24h from activation  they were analyzed by luciferase assay. 
 
AP-1 reporter luciferase assay. Jurkat pRRL-empty and Jurkat pRRL-
146a cells (4 x 10
5
 cells/ ml) were co-transfected with 3µg of AP-1 
reporter construct (a nicely gift from Luca Simeoni) and with 1µg of the 
pRLTK plasmid, using Lipofectamine 2000, according to 
manufacturer’s instructions. 6h after transfection, cells were stimulated 
with αCD3-αCD28 antibodies. After 24h activation cells were analyzed 
by luciferase assay. 
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RESULTS 
 
MiR-146a is up-regulated in activated primary T cells 
 
In order to identify those miRNAs whose expression is triggered 
by T cell activation, we studied the expression profile of miRNAs in 
primary T cells. Using a DNA microarray service provided by LC 
sciences, we analyzed distinct subclasses of  sorted  human primary T 
cell: naive T cells, CD4
+
 memory effectors  and CD4
+
 central memory, 
CD8
+ 
effectors and CD8
+ 
memory effectors (data not shown). 
Array analysis allowed us to focus our attention on a small subset of 
miRNAs which were differentially expressed in the cellular subtypes 
examined. Among the miRNAs which were up-regulated by different 
activation stimuli in primary T cells, there was miR-146a and miR-
146b. The data obtained were validated by Real-Time RT-PCR (qRT-
PCR), using primers which recognized the mature forms of selected 
miRNAs (Fig.1). 
MiR-146 is a family of miRNAs composed by miR-146a and miR-
146b, which differ from each other in their mature sequence only by 
two nucleotides at the 3’end; they are also encoded by two different 
genes on distinct chromosomes. 
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 Fig.1. MiR-146a is up-regulated in differentiated primary T cells: miR-146a and 
miR-146b were measured in primary CD4+ and CD8+ cells by Real-Time qRT-PCR 
 30 
We found that in CD4
+  
memory effectors and CD4
+  
central memory 
miR-146a was up-regulated ofabout 3-9 fold compared to CD4
+
 naive 
cells (Fig.1). Similar higher levels of miR-146a  were observed in CD8
+
 
memory effectors, CD8
+
 central memory  and CD8
+ 
 effectors (Fig.1) 
compared to CD8+ naïve cells. 
On the contrary, no differences of expression were observed for miR-
146b neither in CD8
+
 cells, nor in CD4
+ 
memory effector compared 
with naive cells; the up-regulation of miR-146b was found only in 
CD4
+
 central memory cells (Fig.1). 
 
 
MiR-146a is differentially up-regulated in various stimulation 
conditions  in Jurkat T cells 
 
We next moved towards an in vitro model to focus our attention 
on T lymphocytes activation and for this purpose we chose Jurkat T 
cells as experimental system. 
In order to verify whether activation of T-lymphocytes results into 
induction of miR-146a, we measured miRNAs expression by 
microarray, validating it by Real-Time qRT-PCR.  
As expected, miR-146a and miR-146b levels  were up-regulated in 
Jurkat cells by either PMA+ ionomycin or αCD3- αCD28 antibodies. 
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Fig.2a. Mir-146a expression markedly increases after TCR stimulation: Jurkat cells 
were stimulated with PMA (10ng/ml) and ionomycin (1µg/ml) and miR-146a levels 
were measured at different times by Real-Time qRT-PCR). 
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The fold increase of this up-regulation was quite different between the 
two microRNAs; in fact, miR-146a up-regulation was higher, reaching 
300 fold increase upon PMA and ionomycin stimulation (Fig.2a), 
whereas miR-146b was up-regulated of about 3 fold (data not shown). 
The increase of miR-146a expression was confirmed by Northern blot 
analysis (Supplementary Fig.1). 
The kinetic of miR-146a expression showed that miR-146a levels 
increase 24h after PMA and ionomycin treatment in Jurkat T cells 
reaching a plateau 48h after stimulation (Fig.2a.). 
A similar induction was highlighted by experiments where αCD3 and 
αCD28 antibodies were used to resemble a more physiological 
stimulation of TCR (Fig.2b); in this case however, miR-146a induction 
was less pronounced at 24h, while it was  comparable to that observed 
after PMA and ionomycin stimulation at 72h.  
Since miR-146b expression was not induced in Jurkat cells stimulated 
with αCD3 and αCD28 antibodies (data not shown) we focused our 
analysis on miR-146a. 
In contrast to what observed in Jurkat cells, miR-146a levels in 293T 
cells did not significantly change after stimulation with phorbol esters 
(PMA) (Fig.2c), thus suggesting that the need of an increase in miR-
146a levels following this treatment should require transcription factors 
typically expressed in T lymphocytes. 
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Fig.2b. MiR-146a expression markedly increases after TCR activating stimuli:  
Jurkat cells were stimulated with αCD3 (5µg/ml) and αCD28 (5µg/ml) and miR-146a 
levels were measured at different times by Real-Time qRT-PCR. 
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Fig.2c. PMA- mediated induction of miR-146a is specific for T cells: Jurkat cells 
and 293T cells were stimulated with PMA (10ng/ml) and  miR-146a levels were 
measured at different times by Real-Time qRT-PCR 
 
 
 
MiR-146a is expressed in response to TNF-α inflammatory 
stimulus, but not upon IFN-α stimulation  
 
We tested miR-146a responsiveness to other stimuli, different 
from those which induce T cell activation.  
MiR-146a responsiveness to various pro-inflammatory stimuli has been 
demonstrated in monocytes 
23
. Prompted by these findings, we checked 
miR-146a expression in Jurkat cells stimulated with TNF-α, one of the 
early major cellular mediators in inflammatory response 
71,72
. 
Upon binding of TNF-α to TNFR-1 expressed on T cells several 
pathways are triggered; among them apoptosis and NF-κB- mediated 
inflammation. 
TNF-α induced a significant increase of miR-146a levels (Fig.3a), with 
a kinetic of activation in which an up-regulation of about 3 fold was 
observed 24h after induction. MiR-146a level of expression further 
increased 48h and 72h after induction, reaching ten fold higher levels 
compared to non-treated cells (Fig.3a). 
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Fig.3a. MiR-146a expression  in TNF-α induced Jurkat T cells Jurkat cells ( 5x105 
cells/ml) were stimulated with TNF-α (40ng/ml) and  miR-146a levels were measured 
at different times by Real-Time qRT-PCR 
 
 
This experimental evidence suggested that miR-146a could be involved 
in the inflammatory response in T lymphocytes as was already shown 
in monocytes and B lymphocytes 
23,43
.  
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Fig.3b. MiR-146a is not induced by IFN-α: Jurkat cells (5x105 cells/ml) were 
stimulated with IFN-α alone, with αCD3 (5µg/ml) and αCD28 antibodies (5µg/ml) and 
with a double stimulus IFN-α (20ng/ml) + αCD3 (5µg/ml) and αCD28 antibodies 
(5µg/ml). MiR-146a levels were measured at different times by Real-Time qRT-PCR 
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Another stimulation condition tested in our experiments was IFN-α 
treatment with and without TCR concomitant stimulation, in order to  
assess if miR-146a in T cells was also induced by IFN-α downstream 
effectors, namely STAT proteins. 
Our results show that, in Jurkat cells IFN-α  does not induce miR-146a 
expression and has no effect on miR-146a up-regulation mediated by 
TCR (Fig. 3b). Altogether, our observations suggested that NF-κB and 
AP-1, transcription factors activated by TNF-α signalling, could be 
modulators of miR-146a expression in T lymphocytes in response to 
inflammation. 
 
 
 
Pharmacological approaches indicate TCR signalling 
pathways affecting miR-146a expression 
 
We have shown that miR-146a is up-regulated in Jurkat cells in 
various stimulation condition involving TCR signalling and TNF-α 
mediated induction. 
It has been reported that multiple signalling pathways downstream of 
TCR activation contribute to the induction of early activation genes 
(e.g. IL-2) and therefore we employed various pharmacological 
inhibitors to investigate the contribution of some of these pathways to 
miR146a expression following TCR activation. 
For this purpose, we used three different inhibitors, known to affect 
partially overlapping pathways triggered upon T cell activation. In 
particular we impaired NFAT, NF-κB, JNK and ERK pathways using 
different drugs. 
To ensure that in Jurkat T cells, as in primary T lymphocytes, 
SP600125 behaved as a JNK inhibitor 
73
, we examined its effect on IL-
2 transcription; in fact it has been demonstrated that this drug is able to 
strongly reduce the levels of its transcript 
73
. 
As expected, , IL-2 levels dampened after treatment with SP600125 
(data not shown), while miR-146a levels of expression showed only a 
subtle reduction 24h after TCR stimulation, using various concentration 
of inhibitor (Fig.4a). So this drug did not have a significative effect  on 
αCD3-αCD28-mediated stimulation of miR-146a expression, thus 
demonstrating that AP-1 is not involved in miR-146a modulation. 
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Fig.4a. MiR-146a expression is partially affected by JNK inhibitor: Jurkat cells 
treated with JNK inhibitor for 30 min were induced for 24h with αCD3 (5µg/ml) and 
αCD28 (5µg/ml) antibodies. MiR-146a levels were measured by Real-Time qRT-PCR 
 
 
A similar approach was also used to test PD98059, which specifically 
inhibits MEK1 
73
 and thus the ERK pathway (Fig.4b). 
As reported in other papers 
73
 this drug only attenuates IL-2 expression 
resulting in a 40% inhibition of its mRNA levels (data not shown).  
A similar effect was also observed on miR-146a levels in the presence 
of different concentrations of inhibitor, showing that PD98059 partially 
affected miR-146a expression  in the presence of  CsA 20µM (Fig. 4b). 
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Fig.4b. MiR-146a expression is partially affected by MEK1 inhibitor: Jurkat cells 
treated with MEK1 inhibitor for 30 min were induced for 24h with αCD3 (5µg/ml) and 
αCD28 (5µg/ml) antibodies. MiR-146a levels were measured by Real-Time qRT-PCR 
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Finally, a third pharmacological inhibitor used in our experiments was 
cyclosporine (CsA), a specific Calcineurin inhibitor, able to suppress 
the production of cytokines during T cell activation. In particular CsA 
directly inhibits Calcineurin-mediated activation of NFAT and appears 
to have some effects on AP-1 and NF-kB activity 
73 
(supplementary 
Fig.2). 
As expected treatment with CsA caused a strong reduction of IL-2 
levels (data not shown); we observed also a substantial reduction of 
miR-146a expression (Fig 4c). This finding suggests that at least one of 
the three transcription factors, downstream of Calcineurin (NFAT, AP-
1 and NF- kB) could be involved in modulating miR-146a expression. 
 
 
 
0,00E+00
1,00E-04
2,00E-04
3,00E-04
4,00E-04
5,00E-04
non ind induced non ind +CsA Induced + CsA
m
iR
-1
4
6
a
/U
6
 (
 a
rb
it
ra
ry
u
n
it
s
)
m
iR
-1
4
6
a
/U
6
 (
 a
rb
it
ra
ry
u
n
it
s
)
m
iR
-1
4
6
a
/U
6
 (
 a
rb
it
ra
ry
u
n
it
s
)
m
iR
-1
4
6
a
/U
6
 (
 a
rb
it
ra
ry
u
n
it
s
)
 
 
Fig.4c. Cyclosporine inhibits miR-146a expression:: Jurkat cells (5x105 cells/ml) 
treated with CsA inhibitor (0,5µg/ml) for 30 min were induced for 24h with αCD3 
(5µg/ml) and αCD28 (5µg/ml) antibodies. MiR-146a levels were measured  by Real-
Time qRT-PCR 
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Analysis of miR-146a promoter region upon TCR stimulation 
and TNF-α treatment by a luciferase assay 
 
The experiments illustrated above implicated a transcriptional 
regulation of miR-146a expression following an activating stimulus 
mimicking the TCR-engagement by antigen or in response to TNF-α 
inflammatory stimulus. 
To further address this issue, we extended our study to identify the 
promoter elements which mediated the different responsiveness to these 
two stimuli. We cloned a 1100bp promoter region (Fig 5), mapping 
upstream of the pri-miRNA coding region. This 1100bp construct was 
tested in transient transfection assays in Jurkat cells stimulated either 
with αCD3-αCD28 antibodies (or PMA and ionomycin) or  with TNF-
α. As illustrated in Fig. 5, the region of 1100bp up-stream of miR-146a 
is able to drive expression of a reporter gene, in response to the same 
stimuli leading to miR-146a expression (Fig.2a, 2b and Fig.3a)  
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Fig.5. Effects of PMA+ionomycin, αCD3-αCD28 antibodies and TNF-α on miR-
146a promoter reporter: Luciferase assay on miR-146a 1100bp promoter fragment in 
transfected Jurkat cells, stimulated for 24h with PMA (10ng/ml) and ionomycin 
(1µg/ml), αCD3 (5µg/ml) and αCD28 (5µg/ml) or TNF-α (40ng/ml). Relative promoter 
activity was measured by renilla/firefly Dual Luciferase assay. 
 
 
We then performed a bioinformatic analysis of the promoter sequence 
to identify candidates for the transcriptional regulation of miR-146a. 
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The results of these analyses revealed the existence of putative 
conserved binding sites of interest; among them there were the two NF-
κB sites previously described by Taganov et al. in monocytes 
23
. 
Because of this finding we asked whether the down-modulation of 
miR-146a observed in the presence of CsA (Fig.4c) could depend on 
impairment of NF-κB activity, subsequent to Calcineurin inhibition. 
(supplementary Fig.2). Therefore, we directly tested CsA inhibition on 
the activity of  miR-146a promoter fragment. 
As shown in Fig. 6 CsA affected luciferase expression of miR-146a 
promoter construct determining a two fold decrease of luciferase levels. 
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Fig.6. Cyclosporine down-regulates the 1100bp promoter activity: luciferase assay 
in Jurkat cells (5x105 cells/ml) treated with 0,5µg/µl CsA inhibitor; 24h after 
stimulation (fold induction of αCD3-αCD28 stimulation compared with non induced 
constructs). Relative promoter activity was measured by renilla/firefly Dual Luciferase 
assay 
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Site-directed mutagenesis demonstrates that TCR and TNFα 
stimulation modulate miR-146a expression through partially 
overlapping mechanisms 
 
To further confirm the data obtained with the pharmacological 
approach and to finely map the cis elements required to drive the 
expression of miR-146a, we performed a site directed mutation of the 
relevant consensus sequences within the miR-146a promoter reporter 
construct. In addition to NF-κB, we identified conserved putative 
binding sites, within miR-146a promoter, for some interesting 
transcriptional factors which are known to play a role in T cell 
activation. Among them c-ETS and USF2  binding sites were studied. 
To investigate the contribution of these different binding sites to miR-
146a promoter activity a mutagenesis analysis was performed (Fig.7a). 
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Fig 7a. Promoter region of 1100bp isolated upstream pre-miRNA coding 
sequence: Binding sites mutagenized are here illustrated 
 
 
 
Mutagenized constructs were transiently transfected into Jurkat T cells, 
together with a control vector and the results of the luciferase activity 
was analyzed. As shown in Fig.7b, the mutation of either NF-κB(1) and 
ETS sites almost completely abolished miR-146a promoter activity 
upon TCR stimulation.  
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By contrast, the mutation of NF-κB(2) site had a lower effect on miR-
146a promoter activity. Finally, USF2 site mutation did not affect miR-
146a promoter activity. 
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Fig. 7b. ETS and NF-κB modulate miR-146a expression: Jurkat cells were 
transfected for 48h with the wildtype (wt) or mutagenized (mut) promoter construct and 
with pGL3TK used for normalization of transfection. Cells were stimulated with αCD3 
(5µg/ml) and αCD28 (5µg/ml) antibodies for 24h. Fold induction of αCD3 and αCD28 
stimulation were here illustrated compared with non induced reporter constructs. 
Relative promoter activity was measured by renilla/firefly Dual Luciferase assay. 
(p-value<0,05).  
 
 
Since TNF-α induced miR-146a expression in Jurkat cells (Fig.3a) we 
used  miR-146a promoter construct to test its activity in the presence of 
an inflammatory stimulus. We found that, according to the results 
described above, TNF-α induced miR-146a promoter activity (Fig.7c).  
Mutagenesis analysis showed that the disruption of NF-κB(1) site was 
per se sufficient to determine a complete loss of responsiveness to 
TNF-α stimulation. NF-κB(2) site, instead, had a subsidiary role, 
inducing only a partial reduction of luciferase activity (Fig.7c). 
In contrast to the effects of mutation at the c-ETS site in Jurkat cells 
stimulated with αCD3-αCD28 antibodies (Fig. 7b) or with PMA and 
ionomycin (data not shown), TNF-α stimulation of the promoter 
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reporter was not affected by the ETS mutation (Fig.7c), indicating that 
the ETS site did not play a role in TNF-α response. 
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Fig. 7c. NF-κB is the main transcriptional factor modulating miR-146a expression 
in an inflammatory condition: Jurkat cells were transfected with the wildtype (wt) or 
mutagenized promoter construct (Mut) and with pGL3TK used for normalization of 
transfection. Cells were stimulated with αCD3(5µg/ml)  and αCD28 (5µg/ml) 
antibodies for 24h. Fold induction of αCD3-αCD28 stimulation were here illustrated 
compared with non induced reporter constructs. Relative promoter activity was assayed 
using a renilla/firefly Dual-Luciferase Assay System. (p value< 0,05). 
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MAD-4, FADD and  c-FOS are directly targeted by miR-146a 
 
To examine the functional relevance of miR-146a up-regulation 
in T cells as part of the TCR-mediated activation process, we set out to 
identify miR-146a-regulated genes. We chose a bioinformatics 
approach, using prediction algorithms for the identification of 
microRNA targets. We referred to prediction methods such as 
PicTar
74,75
 and TargetScan
76,77
, both relying heavily on evolutionary 
conservation of the target seed site in mammals. Although conservation 
is a powerful way to improve the sensitivity over background, it is 
clearly not useful for the potentially large class of species-specific 
miRNAs-mRNA interactions which have recently been found 
77
.  
In order to overcome this drawback, we also referred to the miRanda 
algorithm to identify potential binding sites for a given miRNA in 
genomic sequences
 77,78
. Because of the lower level of stringency 
required by miRanda, it gives a larger number of putative targets. 
Among the more than 900 computationally predicted targets for miR-
146a we focussed on genes relevant for T cell biology, predicted by at 
least one of these algorithms. 
We decided to validate the putative targets selected taking advantage of 
a 3’-untranslated region (3’-UTR) luciferase reporter assay.  
We performed luciferase reporter assays on constructs containing the 
firefly luciferase gene, fused to 500bp of the 3’UTR of 22 genes. 
Among them there were: MAD4, BCL11A, LCK, FADD and c-FOS 
(see Supplementary Table 2 for the complete list of putative targets 
analyzed). In particular, we noticed that MAD4 was an interesting 
candidate, because it contained two miR-146a complementary seed site 
in its 3’untraslated region (3’UTR). Moreover, it has been reported that 
MAD4 is down-regulated in T lymphocytes upon TCR stimulation 
79
. 
Another important candidate as miR-146a target was FADD, which has 
only a non conserved seed site and thus it is predicted only by miRanda 
algorithm. Nevertheless, it is noteworthy that the level of 
complementarity between FADD 3’UTR and miR-146a seed 
neighbouring nucleotides was greater than that of other putative targets. 
Finally, c-FOS acts as an important transcription factor, forming a 
heterodimer with c-Jun, commonly known as AP-1
 80
. 
The reporter constructs were transiently transfected together with a 
mimic-146a or with a scramble mimic (see material and methods). 
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The data shown in Fig.8a,b,c demonstrate a miR-146a specific 
regulation of MAD4, FADD and c-FOS luciferase reporters. 
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Fig.8a. MAD4 is targeted by miR-146a: luciferase assay of MAD4 3’UTR in 293T 
cells 24h after transfection The effects of  miR-146a up-regulation were here illustrated 
on wildtype 3’UTR (wt UTR) and on mutated 3’UTR seed match (mutUTR). 
Luciferase activity was assayed using a Dual-Luciferase Reporter System. 
 (p value< 0,05). 
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Fig. 8b. FADD is down-regulated by miR-146a: luciferase assay of FADD 3’UTR in 
293T cells 24h after transfection The effects of  miR-146a up-regulation were here 
illustrated on wildtype 3’UTR (wt UTR) and on mutated 3’UTR seed match (mutUTR) 
(*p value <0,01). 
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The down-regulation observed was specific to the predicted miR-146a 
target sites, as mutation of the 3’UTR seed match sequences relieved 
the inhibitory activity of miR-146a (Fig. 8a,b,c). 
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Fig.8c. c-FOS is targeted by miR-146a: luciferase assay of c-FOS 3’UTR in 293T 
cells 24h after transfection; data were normalized to the value obtained for mimic 
scramble transfected cells The effects of  miR-146a up-regulation were here illustrated 
on wildtype 3’UTR (wt UTR) and on mutated 3’UTR seed match (mutUTR) 
 Luciferase activity was assayed using a Dual-Luciferase Reporter Assay System 
 ( *p value <0,01; **p value< 0,05). 
 
 
 
Given that microRNAs can also promote target mRNA degradation, we 
also tested whether FADD, c-FOS and MAD4 mRNA levels were 
affected by miR-146a over-expression. To do so we measured mRNA 
levels by Real-Time RT-qPCR. MiR-146a over-expressing and control 
Jurkat cells had essentially the same mRNA levels, thus suggesting that 
miR-146a did not promote FADD, MAD4 or c-FOS mRNA decay (Fig. 
8d).  
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Fig.8d. MiR-146a over-expression does not promote mRNAs decay of target genes: 
Jurkat cells ( 5x105 cells/ml) stimulated for 24h with PMA and ionomycin, were 
transfected with mimic-146a or with a scramble mimic; cells were collected 48h after 
transfection. GAPDH mRNA was used to normalize data (Real-Time qRT-PCR).  
 
 
 
These  results gave a good indication that miR-146a was implicated in 
the post-transcriptional down-modulation of MAD4, FADD and c-FOS 
levels; hence the need of further analyses to elucidate the molecular 
phenotypes associated to miR-146a up-regulation. 
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MiR-146a over-expression attenuates AICD in Jurkat cells 
 
To explore the phenotypes associated to miR-146a-mediated 
FADD down-modulation after TCR activation, we looked at possible 
effect on apoptosis. As mentioned above, FADD is an adaptor protein 
mainly involved in the apoptotic process and in particular in AICD in T 
cells. The Jurkat  cell line has been widely used as a model for T cell 
AICD studies, since apoptosis can be easily induced by various 
activating signals. The AICD process, indeed, can be mimicked by 
cross linking the TCR complex with αCD3 antibodies or by activating 
downstream signalling molecules (PKC and Calcineurin) with PMA  
and ionomycin. 
 
76,85% 88,2%
 
 
Fig. 9a. Mimic-146a expressing Jurkat cells are more activated than control 
Jurkat cells: Jurkat cells (5 x105 cells/ml) were stimulated with PMA (10ng/ml) and 
ionomycin (1µg/ml) and 2 x105 cells were stained with CD69-FITC 4h after 
stimulation. Data analysis was performed with FACS- Calibur 
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We transfected Jurkat cells with either mimic-146a or  with scramble 
mimic and induced AICD by stimulating Jurkat cells with PMA and 
ionomycin for 72h. 
We performed a CD69 staining  to monitor the activation status of cells 
early after TCR stimulation. As expected, in non induced cells (both in 
the control cells and in mimic-146a Jurkat cells) CD69 is not expressed. 
As shown in Fig.9a, miR-146a over-expression caused a higher 
expression of CD69, thus evidencing a more activated status of these 
lymphocytes. These findings are in agreement with published studies 
that correlate FADD down-modulation with a higher percentage of 
CD69 positive cells 
62,63
. 
Moreover, when we examined the apoptotic rate of Jurkat cells 
transfected with mimic-146a, 72h after PMA and ionomycin 
stimulation, we found that there was a smaller fraction of apoptotic 
cells compared with the control (Fig. 9b).
 
Taken together, these findings pointed out an anti-apoptotic role of 
miR-146a, here demonstrated in T lymphocytes, possibly due to FADD 
down-modulation, as suggested by 3’UTR-FADD luciferase assay (Fig. 
8b).  
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Fig.8b. MiR-146a acts as an anti-apoptotic factor: AnnV+-PI+ double staining  in 
Mimic146a cells compared with scramble mimic control cells (FACS analysis). 
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MiR-146a affects AP-1 activity as revealed by a luciferase reporter 
assay 
 
To further investigate the effect of mir-146a on c-FOS expression 
we performed a luciferase assay using an AP-1 reporter plasmid, 
transiently transfected in pRRL-146a Jurkat cells. 
pRRL-146a Jurkat cells are transduced with a lentiviral construct, 
which allows a stable expression of miR-146a of about 3 fold compared 
with Jurkat cells expressing the pRRL(-) empty lentiviral construct.  
pRRL-146a Jurkat cells were stimulated with αCD3-αCD28 antibodies 
for 24 hours. As illustrated on Fig.10, the over-expression of miR-146a 
impairs AP-1 transcriptional activity. 
This result is consistent with the observation that c-FOS is down-
modulated by miR-146a (Fig. 8c) and indicates the involvement of 
miR-146a in the modulation of AP-1 activity after T cell activation  
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Fig10. AP-1 activity is down-modulated by miR-146a: luciferase reporter assay on 
lentiviral transduced Jurkat cells, over-expressing miR-146a (pRRL-146a) compared 
with control Jurkat cells (pRRL-);  cells were stimulated with αCD3-αCD28 antibodies 
for 24h. Luciferase activity was assayed using a renilla/firefly Dual-Luciferase Reporter 
Assay System. (p value< 0,05). 
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DISCUSSION 
 
The critical role played by miRNAs in immunity has emerged in the 
last years 
14,18,21
. 
In the present study we found that miR-146a is expressed in primary 
CD4
+
 and CD8
+
 T lymphocytes, but not in naive T cells (Fig.1). This 
first experimental evidence, suggesting the induction of miR-146a 
expression upon TCR stimulation, prompted us to further investigate a 
possible role of miR-146a in T cell activation.  
We detected up-regulation of MiR-146a levels in Jurkat T cells, 
stimulated with PMA and ionomycin or with αCD3-αCD28 antibodies, 
which mimic antigen recognition by TCR (Fig.2a,2b).  
Therefore, we attempted to elucidate the pathways involved in miR-
146a transcriptional regulation using Jurkat cells as an experimental 
model. A first approach consisted in the treatment of Jurkat cells with 
specific pharmacological inhibitors, interfering with the main pathways 
triggered by TCR signalling: NFAT, AP-1, ERK and NF-κB pathways. 
We found that cyclosporine, a Calcineurin inhibitor, significantly 
impaired miR-146a up-regulation (Fig.4c), thus suggesting that the 
pathways affected by CsA play a key role in the induction of miR-146a 
upon TCR engagement. This observation prompted us to further 
investigate with molecular tools the transcription factors which are 
responsible for miR-146a expression in T lymphocytes. 
A deeper investigation of miR-146a promoter region,  through a 
bioinformatic analysis and a luciferase assay, allowed us to carefully 
characterize the cis regulatory elements involved in miR-146a 
transcriptional regulation. First we identified conserved consensus sites 
for T lymphocytes specific transcription factors, which are involved in 
pathways triggered by TCR signalling; in particular two sites for NF-
κB, one site for c-ETS and one site for USF2 (Fig.7a). Subsequently, 
mutational analysis of the promoter region indicated that NF-κB and c-
ETS binding sites are relevant for the modulation of miR-146a 
expression upon TCR stimulation (Fig.7b.) . 
Both NF-κB  and c-ETS are transcription factors fundamental for 
transmitting  TCR activation signals in the T lymphocytes
 81,82
 and play 
a key role in modulating the expression of several cytokines (e.g. IL-2 
and IL-12). Therefore, our finding that these two transcriptional factors 
strongly affect the expression of miR-146a provide a further link 
between miR-146a and T lymphocytes activation. 
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Since miR-146a has been shown to be induced in monocytes by 
inflammatory stimuli 
23
, we analyzed miR-146a expression in Jurkat 
cells treated with TNF-α, one of the early major cellular mediators in 
inflammatory and immuno-modulatory responses. Our observation that 
miR-146a is up-regulated following TNF-α stimulation (Fig.3a) and 
that, in this condition, NF-κB is the only main activator responsible of 
miR-146a promoter activation (Fig.7c), indicate a role of miR-146a in 
the modulation of the inflammatory response also in T lymphocytes.  
Therefore, we have shown that at least two different signals drive miR-
146a expression in Jurkat cells: TCR  stimulation and inflammation 
(Fig.5). We demonstrated that these two signals use partially 
overlapping transcriptional mechanisms to induce miR-146a 
expression. In particular, NF-κB, the main transcription factor activated 
by TNF-α during the inflammatory response, is the activator of miR-
146a expression in the inflammatory context, while during TCR 
activation the contribution of both NF-κB and c-ETS is indispensable. 
The study of miR-146a molecular functions also represents a 
stimulating challenge ad so we aimed to elucidate the fine-tune 
regulation exerted by miR-146a in some important biological aspects of 
T cell immune response. 
MiR-146a down-regulate FADD expression at posttranscriptional level 
as demonstrated by  luciferase reporter assays performed using the 3’-
UTR of FADD (Fig.8b). Moreover, miR-146a over expression in Jurkat 
cells determined a more activated status of cells, as revealed by a higher 
expression of CD69
+
 marker (Fig.9a),
 
and a decrease of the apoptotic 
rate
 
(Fig.9b). Notably, both of these phenotypes are consistent with a 
down-regulation of FADD. 
For the first time, we have shown that other signaling pathways, apart 
from inflammation, are influenced by miR-146a modulation and 
function. Indeed, we provided experimental evidences that support a 
role for miR-146a in modulating AICD, through the down-regulation of 
FADD. 
We also showed miR-146a involvement in other pathways related to T 
cell activation, in particular we demonstrated through luciferase assays 
that MAD4 and c-FOS are down-modulated by miR-146a (Fig.8a,8c). 
MAD4 is a member of the MADs family, a negative regulator of MYC 
function 
83,84 
and it promotes differentiation and suppresses the 
development of cancer in vivo 
81
. Moreover, it was reported that in T 
lymphocytes MAD4 is down-regulated upon TCR stimulation
79
. It 
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would be intriguing to unravel which is the contribution of MAD4 
down-regulation to the phenotype of miR-146a over-expressing cells; 
this aspect will be further investigated in following studies. 
We focused on c-FOS, being an interesting transcriptional factor, which 
modulate the expression of several cytokines, important for T cell 
differentiation. The luciferase assay validating it as a target of miR-
146a (Fig.8c) is consistent with the observation that miR-146a over-
expression impairs AP-1 activity after T cell activation (Fig.10) 
This result was obtained using a luciferase reporter vector for AP-1 
transfected in the lentiviral pRRL-146a Jurkat cells (see material and 
methods). An advantage of the experimental approach here adopted is 
that in pRRL-146a Jurkat cell line, the expression levels of miR-146a 
are not as elevated as in the case of transient transfection of the mimic-
146a (about 700 fold; Supplementary. Fig.3), thus demonstrating that 
even a modest up-regulation of miR-146a (3 fold) is sufficient to exert 
its modulatory effect on AP-1 activity. 
This work illustrated a framework of an intriguing scenario, in which 
miR-146a contributes to the modulation of T cell function by fine 
tuning complex signaling networks, delimiting the intensity and 
duration of such signaling.  
A focus for future studies will be the elucidation of the molecular 
mechanism of miR-146a action, thereby demonstrating a direct 
correlation between FADD repression and AICD impairment, both 
mediated by miR-146a. 
Moreover, it would be very interesting to analyze interleukins levels in 
stimulated  Jurkat cells over-expressing miR-146a, according to the 
molecular phenotype associated with c-FOS down-regulation, being 
AP-1 heterodimer an important modulator of IL-2 expression 
80
. 
Therefore, many other questions regarding miR-146a still await 
answering. Understanding its functions in the complex molecular 
networks which orchestrate T cell immune response will contribute not 
only to a better comprehension of immune homeostasis but will identify 
novel targets for modulating  immune response and inflammation in 
humans. 
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Supplemental Data 
 
 
Suppl. Fig 1: Northern Blot: miR-146a expression in Jurkat cells stimulated with PMA 
(10ng/ml) and ionomycin (1µg/ml) for different times.  
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Suppl. Fig2. NF-κB reporter activity is inhibited by CsA: Jurkat cells were 
transfected with a NF-κB reporter plasmid and the day after transfection they were 
treated for 30 minutes with CsA (0,5µg/µl) and then stimulated with αCD3 (5µg/ml) 
and αCD28 (5µg/ml) for 24h. The luciferase assay was performed 48h after 
transfection. Fold induction of stimulation were here illustrated compared with non 
induced reporter construct. Relative NF-κB reporter activity was assayed using a 
renilla/firefly-Luciferase Reporter Assay System. (p value< 0,05). 
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Suppl. Fig3. Mimic-146a transfected Jurkat cells over-expresses miR-146a Jurkat 
cells were transiently transfected with miR-146a mimic or with a scramble mimic. iR-
146a levels were measured 48h after transfection by RT-qReal Time-PCR 
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Supplementary Table 1. List of oligonucleotides (*LNA bases are preceded 
by a “+” symbol) 
 
 
RT-qPCR analysis 
 
*PCR for LNA U6 
5’-GCTTCGGCAGCACATATACT-3’ 
U6 template PCR 
5’-GCTTCGGCAGCACATATACTAAAATTGGAACGATACAGAG 
AAGATTAGCATGGCCC-3’ 
PCR rev miR-146b  
5’-CAGAGGTACGATAGTCAAGG 
mir-146b template PCR 
 5’-CAGAGGTACGATAGTCAAGGAGCCTATGGTTCAGTTCTCA-3’ 
*PCR for LNA mir-146b 
 5’-T+GA+GAA+CTGAATTCCATA-3’ 
RT miR-146b 
5’- CAGAGGTACGATAGTCAAGGAGCCTATGG-3’ 
PCR rev/ RT U6 
5’-GAATTTGCGTGTCATCCTTG-3’ 
PCR revmiR-146a 
 AACAACGAGTGCTATGGAAT 
*PCR for LNA mir-146a 
 5’-T+GA+GA+ACTGAATTCCATG-3’ 
PCR rev miR-146a  
5’-TGAGAACTGAATTCCATGGGTT-3’ 
miR-146a template PCR 
 5’AACAACGAGTGCTATGGAATAACCCATGGAATTCAGTTCTCA-3’ 
MAD4-pcrFOR 
 5’-ACAACAGGTCTTCACACAAC-3’ 
MAD4_pcrREV  
CTCCTCCAGTTTCTTGATG-3’ 
FADD pcr FOR 
5’-TGCGGGAGTCACTGAGAATC-3’ 
FADD pcr REV 
5’-CAGCCACCAGGTTCATCTG-3’ 
FOS pcrFOR 
5’-AGCGGAGACAGACCAACTAG-3’ 
 
FOS pcr REV 
5’-GCTGCCAGGATGAACTCTAG-3’ 
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3'UTR luciferase assays 
 
FADDutrFOR 
5’- GCGCGCTCTAGAGGACCACAGGCATCTACACA-3’ 
FADDutrREV  
5’-GCGCGCGAGAGGAGACTCAACTCACA-3’ 
 FADD mut FOR 
5’-CTAGAGGACCACAGGCATCTACACAAGATATCCTTTGGTTCTCTCAGGAAG 
GTACC-3’ 
FADD mut REV 
5’-GCTACCTTCCTGGAGAGAACCAAAGGATATCTTGTGTAGATCCTGTGGTCCT 
CTAG-3’ 
MAD4utrFOR 
 5’-GCGCGCTCTAGATGCCTGCCCGCCAGCCAC-3’ 
MAD4utrREV 
 5’-GCGCGCCTCACCCAGTTCCCGCCCTT-3’ 
MAD4 mut FOR 
5’-CAGCCACGCGTGTCAGCCCTCCGCCATGGCTTCAGTTGACGCCA-3’ 
MAD4 mut REV 
5’-GAGAGGCTGGCGTCAACTGAAGCCATGGCGGAGGGCTGACACGCGTGGCTG-3’ 
IRAK1utrFOR 
 5’-GCGCGCTCTAGAGTTCACCTGGGCAGATCC-3’ 
IRAK1utrREV 
 5’-GCGCGCGATGATGCCAGCCTTCCT-3’ 
FOS mut FOR 
 5’-GAGGTGGTCTGAATGTTCTGACATTAATCCATGAAAACGTT-3’ 
FOS mut REV 
 5’-AACGTTTTCATGGATTAATGTCAGAACATTCAGACCACCTC-3’ 
GAPDH FOR 
5’-GAAATCCCATCACCATCTTCCAGG-3’ 
GAPDH REV 
5’-GAGGCCCAGCCTTCTCCATG-3’ 
 
Northern oligonucleotides 
 
northern marker miR-146a  
5’-TGAGAACTGAATTCCATGGGTT-3’ 
northern probe miR-146a  
5’-AATTCAGTTCTCA-3’ 
northern probe U6 
5’-AGTATATGTGCTGCCGAAGC-3’ 
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MiR-146a promoter luciferase assays 
 
NFKB1 mut rev  
5’-CCCTCTCTGGAAAGTGGTTTCTAGATCCCTCCTCGGC-3’ 
NFKB1 mut for  
5’-GCCGAGGAGGGATCTAGAAACCACTTTCCAGAGAGGG-3’ 
ETS mut for 
 5’-GCGGAGAGTACAGACGCCTGGGGACCCAGC-3’ 
ETS mut rev  
5’-GCTGGGTCCCCAGGCGTCTGTACTCTCCGC-3’ 
NFKB mut for 
 5’-AGCCGATAAAGCTCTCACCATTTCCCCGCGGGGC-3’ 
 
NFKB2 mut rev  
5’-GCCCCGCGGGGAAATGGTGAGAGCTTTATCGGCT-3’ 
USF mut for  
5’-AGGAAGATTTCTCAGTGTTCCAAGTGCCAGGTCAGTTTACAGTTC-3’ 
USF mut rev 
 5’-GAACTGTAAACTGACCTGGCACTTGGAACACTGAGAAATCTTCCT-3’  
 
Seq luc for 
 5’-GTGGATTACGTCGCCAGTC-3’ 
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Supplementary Table2a. predicted targets cloned for 3’UTR luciferase assays  
tr
an
sc
ri
pt
io
n
fa
ct
or
co
m
pl
ex
, R
N
A
 p
ol
ym
er
as
e
II
 t
ra
ns
cr
ip
ti
on
fa
ct
or
ac
tiv
it
y,
 m
ac
ro
ph
ag
e
di
ff
er
en
tia
tio
n,
 
se
qu
en
ce
-s
pe
ci
fi
c
D
N
A
 b
in
di
ng
,
T
ra
ns
cr
ip
tio
n
fa
ct
or
Sp
i-
B
.
SP
IB
m
iR
an
da
(m
iR
ba
se
),
 
Pi
ct
ar
, 
T
ar
ge
ts
ca
n
tr
an
sc
ri
pt
io
n
co
re
pr
es
so
r
ac
tiv
it
y,
T
 c
el
ld
if
fe
re
nt
ia
ti
on
, c
yt
op
la
sm
, B
 c
el
ld
if
fe
re
nt
ia
tio
n,
 h
em
op
oi
es
is
, z
in
c
io
n
bi
nd
in
g,
 n
uc
le
ic
ac
id
 b
in
di
ng
, m
et
al
 io
n
bi
nd
in
g
B
-c
el
ll
ym
ph
om
a/
le
uk
em
ia
11
A
 (
B
-
ce
ll
C
LL
/l
ym
ph
om
a
11
A
)
B
C
L
11
A
T
ar
ge
tS
ca
n,
 
Pi
cT
ar
tr
an
sc
ri
pt
io
n
co
ac
ti
va
to
r
ac
tiv
it
y,
re
gu
la
ti
on
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 p
ol
ym
er
as
e
II
 p
ro
m
ot
er
, z
in
c
io
n
bi
nd
in
g,
 m
et
al
 io
n
bi
nd
in
g
K
ru
ep
pe
l-
lik
e
fa
ct
or
7 
(U
bi
qu
ito
us
kr
ue
pp
el
-l
ik
e
fa
ct
or
).
K
L
F
7
m
iR
an
da
(m
iR
ba
se
),
 
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
ne
ga
ti
ve
 r
eg
ul
at
io
n
of
 c
el
lp
ro
li
fe
ra
tio
n,
 S
M
A
D
 p
ro
te
in
he
te
ro
m
er
iz
at
io
n,
 tr
an
sc
ri
pt
io
n
co
fa
ct
or
ac
ti
vi
ty
, D
N
A
-
de
pe
nd
en
t, 
tr
an
sc
ri
pt
io
n,
 c
yt
op
la
sm
, p
ro
te
in
bi
nd
in
g,
 p
os
iti
ve
 r
eg
ul
at
io
n
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 p
ol
ym
er
as
e
II
 
pr
om
ot
er
M
ot
he
rs
ag
ai
ns
td
ec
ap
en
ta
pl
eg
ic
ho
m
ol
og
4 
(S
M
A
D
 4
) 
SM
A
D
4
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
ne
ga
ti
ve
 r
eg
ul
at
io
n
of
 c
el
lp
ro
lif
er
at
io
n,
 p
ro
te
in
bi
nd
in
g,
 n
eg
at
iv
e 
re
gu
la
ti
on
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 
po
ly
m
er
as
e
II
 p
ro
m
ot
er
, n
uc
le
us
, D
N
A
 b
in
di
ng
M
X
D
4
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
va
lid
at
ed
ta
rg
et
in
te
rl
eu
ki
n-
1 
re
ce
pt
or
co
m
pl
ex
, t
ra
ns
m
em
br
an
e
re
ce
pt
or
pr
ot
ei
n
se
ri
ne
/t
hr
eo
ni
ne
ki
na
se
si
gn
al
in
g
pa
th
w
ay
, s
ig
na
l
tr
an
sd
uc
ti
on
, t
ra
ns
cr
ip
tio
na
la
ct
iv
at
or
ac
tiv
it
y,
 p
ro
te
in
am
in
o 
ac
id
 a
ut
op
ho
sp
ho
ry
la
ti
on
, p
os
iti
ve
 r
eg
ul
at
io
n
of
 
tr
an
sc
ri
pt
io
n,
 N
F
-k
ap
pa
B
-i
nd
uc
in
g
ki
na
se
ac
ti
vi
ty
, p
ro
te
in
se
ri
ne
/th
re
on
in
e
ki
na
se
ac
ti
vi
ty
, m
ag
ne
si
um
io
n
bi
nd
in
g,
 tr
ns
fe
ra
se
ac
ti
vi
ty
, a
ct
iv
at
io
n
of
 N
F-
ka
pp
aB
-i
nd
uc
in
g
ki
na
se
.
In
te
rl
eu
ki
n-
1 
re
ce
pt
or
-a
ss
oc
ia
te
d
ki
na
se
1 
(I
R
A
K
-1
).
IR
A
K
1
m
iR
an
da
(m
iR
ba
se
) 
T
ar
ge
tS
ca
n
pa
rt
1
tr
an
sc
ri
pt
io
n
fa
ct
or
co
m
pl
ex
, R
N
A
 p
ol
ym
er
as
e
II
 t
ra
ns
cr
ip
ti
on
fa
ct
or
ac
tiv
it
y,
 m
ac
ro
ph
ag
e
di
ff
er
en
tia
tio
n,
 
se
qu
en
ce
-s
pe
ci
fi
c
D
N
A
 b
in
di
ng
,
T
ra
ns
cr
ip
tio
n
fa
ct
or
Sp
i-
B
.
SP
IB
m
iR
an
da
(m
iR
ba
se
),
 
Pi
ct
ar
, 
T
ar
ge
ts
ca
n
tr
an
sc
ri
pt
io
n
co
re
pr
es
so
r
ac
tiv
it
y,
T
 c
el
ld
if
fe
re
nt
ia
ti
on
, c
yt
op
la
sm
, B
 c
el
ld
if
fe
re
nt
ia
tio
n,
 h
em
op
oi
es
is
, z
in
c
io
n
bi
nd
in
g,
 n
uc
le
ic
ac
id
 b
in
di
ng
, m
et
al
 io
n
bi
nd
in
g
B
-c
el
ll
ym
ph
om
a/
le
uk
em
ia
11
A
 (
B
-
ce
ll
C
LL
/l
ym
ph
om
a
11
A
)
B
C
L
11
A
T
ar
ge
tS
ca
n,
 
Pi
cT
ar
tr
an
sc
ri
pt
io
n
co
ac
ti
va
to
r
ac
tiv
it
y,
re
gu
la
ti
on
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 p
ol
ym
er
as
e
II
 p
ro
m
ot
er
, z
in
c
io
n
bi
nd
in
g,
 m
et
al
 io
n
bi
nd
in
g
K
ru
ep
pe
l-
lik
e
fa
ct
or
7 
(U
bi
qu
ito
us
kr
ue
pp
el
-l
ik
e
fa
ct
or
).
K
L
F
7
m
iR
an
da
(m
iR
ba
se
),
 
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
ne
ga
ti
ve
 r
eg
ul
at
io
n
of
 c
el
lp
ro
li
fe
ra
tio
n,
 S
M
A
D
 p
ro
te
in
he
te
ro
m
er
iz
at
io
n,
 tr
an
sc
ri
pt
io
n
co
fa
ct
or
ac
ti
vi
ty
, D
N
A
-
de
pe
nd
en
t, 
tr
an
sc
ri
pt
io
n,
 c
yt
op
la
sm
, p
ro
te
in
bi
nd
in
g,
 p
os
iti
ve
 r
eg
ul
at
io
n
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 p
ol
ym
er
as
e
II
 
pr
om
ot
er
M
ot
he
rs
ag
ai
ns
td
ec
ap
en
ta
pl
eg
ic
ho
m
ol
og
4 
(S
M
A
D
 4
) 
SM
A
D
4
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
ne
ga
ti
ve
 r
eg
ul
at
io
n
of
 c
el
lp
ro
lif
er
at
io
n,
 p
ro
te
in
bi
nd
in
g,
 n
eg
at
iv
e 
re
gu
la
ti
on
of
 t
ra
ns
cr
ip
ti
on
fr
om
R
N
A
 
po
ly
m
er
as
e
II
 p
ro
m
ot
er
, n
uc
le
us
, D
N
A
 b
in
di
ng
M
X
D
4
Pi
cT
ar
, 
T
ar
ge
tS
ca
n
va
lid
at
ed
ta
rg
et
in
te
rl
eu
ki
n-
1 
re
ce
pt
or
co
m
pl
ex
, t
ra
ns
m
em
br
an
e
re
ce
pt
or
pr
ot
ei
n
se
ri
ne
/t
hr
eo
ni
ne
ki
na
se
si
gn
al
in
g
pa
th
w
ay
, s
ig
na
l
tr
an
sd
uc
ti
on
, t
ra
ns
cr
ip
tio
na
la
ct
iv
at
or
ac
tiv
it
y,
 p
ro
te
in
am
in
o 
ac
id
 a
ut
op
ho
sp
ho
ry
la
ti
on
, p
os
iti
ve
 r
eg
ul
at
io
n
of
 
tr
an
sc
ri
pt
io
n,
 N
F
-k
ap
pa
B
-i
nd
uc
in
g
ki
na
se
ac
ti
vi
ty
, p
ro
te
in
se
ri
ne
/th
re
on
in
e
ki
na
se
ac
ti
vi
ty
, m
ag
ne
si
um
io
n
bi
nd
in
g,
 tr
ns
fe
ra
se
ac
ti
vi
ty
, a
ct
iv
at
io
n
of
 N
F-
ka
pp
aB
-i
nd
uc
in
g
ki
na
se
.
In
te
rl
eu
ki
n-
1 
re
ce
pt
or
-a
ss
oc
ia
te
d
ki
na
se
1 
(I
R
A
K
-1
).
IR
A
K
1
m
iR
an
da
(m
iR
ba
se
) 
T
ar
ge
tS
ca
n
pa
rt
1
 
 59 
Supplementary Table2b .predicted targets cloned for 3’UTR luciferase assays 
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